Propanc Biopharma Inc. announced its strategic plans for 2026, focusing on the continued clinical development of its lead asset, PRP, and the expansion of its scientific platform into additional therapeutic areas with high unmet medical need. The company is also advancing its pipeline with the development of a fully synthetic backup compound, Rec-PRP. Propanc intends to further strengthen its intellectual property portfolio, with three new patent applications entering the national phase in multiple jurisdictions. Ongoing research collaborations with the Universities of Jaén and Granada are expected to support these initiatives. The company aims to create long-term value through these activities and maintain regular communication with shareholders as progress is made.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624636-en) on January 13, 2026, and is solely responsible for the information contained therein.